ReviewNeuro-oncology advances
Circulating tumor DNA as a liquid biopsy for glioma detection in cerebrospinal fluid and plasma: A systematic review and meta-analysis.
Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurate molecular characterization of gliomas is essential for determining prognosis and guiding therapeutic decisions. In recent years, liquid biopsy for analysis of circulating tumor DNA (ctDNA) in blood or cerebrospinal fluid (CSF) has emerged as a promising, minimally invasive alternative. This study evaluates the existing literature on the utility of ctDNA detection in CSF and blood in patients with gliomas, with the goal of assessing its ability to identify mutations concordant with those detected in tumor tissue. Methods: A systematic search was conducted up to April 30, 2026, to identify cohorts that evaluated the effectiveness of ctDNA-based liquid biopsies for gliomas. The primary assessed outcomes were the sensitivity and specificity of the liquid biopsies using CSF or plasma. A pooled sensitivity analysis was performed, as well as summary receiver operating characteristic (SROC) curves. Results: Twenty-eight studies met the inclusion criteria, encompassing 613 patients. Meta-analysis of diagnostic performance revealed improved biomarker performance for CSF (Area under the curve [AUC] 0.95) ctDNA. Pooled sensitivity for ctDNA detection in patients with gliomas was higher in CSF 0.79 (95% CI, 0.69-0.85) than in plasma 0.29 (95% CI, 0.15-0.47), Conclusion: The literature demonstrates a promising performance of ctDNA analysis in patients with diffuse gliomas as a liquid biopsy strategy. CSF ctDNA analysis exhibited superior sensitivity compared to plasma ctDNA. This meta-analysis supports the utility of ctDNA, particularly CSF ctDNA, as a complementary diagnostic tool in neuro-oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.